Clinical trials: Dyslipidaemias
Dyslipidaemias
A Study in Healthy Volunteers of Single Doses of Orally Administered Investigational Product to Investigate Safety, Tolerability, and Pharmacokinecs.
This study is the first study in humans to assess the safety and tolerability of various doses of GSK1292263 alone, and taken with sitigliptan.
- Trial name
- NCT00783549
- Testing
- an undetermined dose of GSK1292263, ascending dose of GSK1292263
- Where
- United States
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Patient With Dyslipidemia
Assessment of Compliance With European and French Guidelines for the Management of Dyslipidaemias
Cardiovascular disease (CVD) due to atherosclerosis of the arterial vessel wall and to thrombosis is the foremost cause of premature mortality and of disability-adjusted life years in Europe, and is also increasingly common in…
- Trial name
- OBDYSLIP (NCT03449784)
- Testing
- Detection of patients with dyslipidemia
- Where
- France
- Volunteers
- 977 people
- Sponsor
- University Hospital, Montpellier
Healthy Subjects, Dyslipidaemias
Study Of Pharmacokinetics and Pharmacodynamics Effects Of GSK256073A On Healthy Volunteers
The purpose of this study is to compare the effects of single and repeat doses of GSK256073 with placebo in HVT subjects.
- Trial name
- NCT00488449
- Testing
- GSK256073A tablets
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy Subjects, Dyslipidaemias
Study To Evaluate The Effects Of GW856553 On Endothelial Function/Vascular Compliance In Subjects With Dyslipidaemia.
The rationale for this study is to determine whether GW856553 (7.5mg BD for 28 days) has an effect on endothelial function in dyslipidaemic subjects as assessed by venous occlusion plethysmography using brachial artery…
- Conditions
- Healthy Subjects, Dyslipidaemias, Dyslipidaemia
- Trial name
- NCT00474864
- Testing
- GW856553
- Where
- 3 sites in United Kingdom
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy Subjects, Dyslipidaemias
A Study To See If GSK256073A Can Block Niacin-Induced Flushing In Healthy Volunteers
To test the ability of GSK256073 to block niacin-induced flushing when GSK256073 and niacin are co-administered as single doses to HVTs.
- Trial name
- NCT00608699
- Testing
- GSK256073A tablets + IR niacin tablets
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Dyslipidaemias, Dyslipidaemia
GW501516 In Subjects Who Have Low Level Of High-Density Lipoprotein Cholesterol
The purpose of this clinical research study is to compare up to 3 doses of an investigational drug GW501516 to placebo (an inactive pill that looks like GW501516) to see if it is safe, well tolerated and effective in improving…
- Trial name
- NCT00158899
- Testing
- GW501516 oral tablets
- Where
- 64 sites in Belgium, Denmark and 9 more
- Volunteers
- 424 people
- Sponsor
- GlaxoSmithKline
Dyslipidaemias, Heart Failure
Effect Of GW501516X On How The Heart Obtains And Uses Energy
The purpose of this study is to determine the effect of a 4-week treatment period with GW501516X on how the heart obtains and uses energy. The energy of the heart will be measured by Magnetic Resonance Imaging (MRI).
- Trial name
- NCT00318617
- Testing
- GW510516X
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Dyslipidaemias, Dyslipidemias
A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Administering Multiple Oral Doses of GSK1292263 Alone and With Atorvastatin
This study investigates the safety, pharmacokinetics and effects of GSK1292263 when taken alone or when co-dosed with atorvastatin to subjects with dyslipidemia.
- Trial name
- NCT01218204
- Testing
- 10mg atorvastatin, 80mg atorvastatin, 100mg GSK1292263
- Where
- 21 sites in United States
- Volunteers
- 287 people
- Sponsor
- GlaxoSmithKline
Hypercholesterolemia, Dyslipidaemias
An Exploratory Study To Look At The Effect Of Two Investigational Drugs On Body Fat And Inflammation
The investigational drugs administered in this study activate proteins called PPARs. Data in the scientific literature on PPARs, as well as animal data and early clinical data generated by GSK with these drugs, suggest that…
- Conditions
- Hypercholesterolemia, Dyslipidaemias, Obesity
- Trial name
- NCT00388180
- Testing
- GW501516, GW590735
- Where
- United States
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Dyslipidaemias, Carotid Artery Stenoses
Improved Medication and Care to Achieve Lipid Targets After Carotid Surgery
The goal of this clinical trial is to find out if patients who receive extra support stay on their cholesterol-lowering therapy and therefore have lower cholesterol levels after 4 months.
- Trial name
- IMACS (NCT07064135)
- Testing
- Prompt Medication Adjustment and Intensive Follow-up, Standard Care
- Where
- Austria
- Volunteers
- 50 people
- Sponsor
- Barmherzige Brüder Linz
Dyslipidaemias, Dyslipidemias
Study to Test GSK256073 in Patients With Dyslipidemia
This is a two part study (Part A and Part B) that will first aim to establish the PK/PD relationship between exposure and lipid effects (Part A: 75 subjects), and will then confirm the effect using the most relevant dose(s) (Part…
- Trial name
- NCT00903617
- Testing
- GSK256073, Niaspan
- Where
- 11 sites in United States
- Volunteers
- 80 people
- Sponsor
- GlaxoSmithKline
Dyslipidemias, Hyperglycemia
Role of Ajwa Derived Polyphenols in Dyslipidaemias
World Health Organization report notifies of the escalating global burden of cardiovascular diseases (CVD), projecting that it will become the major worldwide cause of death and disability by 2020.
- Conditions
- Dyslipidemias, Hyperglycemia, Liver Dysfunction, Oxidative Stress
- Trial name
- NCT03805139
- Testing
- Ajwa Date (phoenix dactylifera)
- Where
- Pakistan
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Aga Khan University
Dyslipidaemias
Dyslipidemia Study Investigating The Increase In "Good Cholesterol"
An eight week comparison of the investigational drug GW590735, placebo, and the marketed drug fenofibrate intended to increase the levels of "good cholesterol" and decrease levels of "bad cholesterol" in healthy patients with low…
- Trial name
- NCT00169559
- Testing
- GW590735, fenofibrate
- Where
- 50 sites in United States, Canada
- Volunteers
- 250 people
- Sponsor
- GlaxoSmithKline
Dyslipidaemias
The Efficacy of a Food Supplement Consisting of the Combination of an Olive Extract and a Myrtle Extract for the Improvement of Lipid Metabolism in Subjects With Slightly Altered Cholesterolemia Values
Study Objective The aim of the study is to evaluate the efficacy of a dietary supplement based on a mixture of olive (Olea europaea L., fruit) and myrtle (Myrtus communis L., leaves) extracts in maintaining normal plasma…
- Trial name
- COLTECH25 (NCT07668791)
- Testing
- Food supplement (T1675)
- Where
- Italy
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- Labomar SPA
Dyslipidaemias
Repeat Dose Food Effect Study of GSK256073F in Healthy Adult Subjects
The purpose of this study is to compare the effects of fasting and fed conditions with repeat doses of GSK256073F in HVT subjects.
- Trial name
- NCT00808093
- Testing
- GSK256073
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy Subjects, Dyslipidaemias
A Second Study to Determine the Effect of GSK256073A on HVTs
The purpose of this study is to compare the effects of single and repeat doses of GSK256073 with placebo in HVT subjects that have been administrated GSK256073 in the HMA107787 study
- Trial name
- NCT00551694
- Testing
- GSK256073A tablets
- Where
- United States
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline